Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 8, 2012, Pages 2907-2915

  Ciresi, A ^a   Amato, M C ^a   Pizzolanti, G ^a   Giordano Galluzzo, C ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; GROWTH HORMONE; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 6; LEPTIN; SARTAN DERIVATIVE; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

ACROMEGALY; ADULT; AGE; AGED; ANALYTIC METHOD; ANALYTICAL PARAMETERS; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HUMAN; HYPERINSULINEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; MALE; METABOLIC SYNDROME X; MIXED MEAL TOLERANCE TEST; ORAL DISPOSITIONAL INDEX; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; TUMOR VOLUME; VISCERAL ADIPOSITY INDEX;

ACROMEGALY; ADIPOKINES; ADIPOSITY; ADULT; AGED; AREA UNDER CURVE; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED;

EID: 84864808077     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1518     Document Type: Article

References (44)

1. Giustina A, Veldhuis JD 1998 Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19:717-797 (Pubitemid 128506521)
2. Clemmons DR 2002 Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly. Pituitary 5:181-183 (Pubitemid 36656431)
3. Szego CM, White 1948 A The influence of purified growth hormone on fasting metabolism. J Clin Endocrinol Metab 8:594
4. Freda PU, Shen W, Heymsfield SB, Reyes-Vidal CM, Geer EB, Bruce JN, Gallagher D 2008 Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. J Clin Endocrinol Metab 93:2334-2343 (Pubitemid 351831556)
5. Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A; For the AlkaMeSy Study Group 2010 Visceral Adiposity Index (VAI): A Reliable Indicator Of Visceral Fat Function Associated With Cardiometabolic Risk. Diabetes Care 33:920-922
6. Boden G 1997 Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10 (Pubitemid 27009941)
7. Mathieu P, Pibarot P, Larose E, Poirier P, Marette A, Després JP 2008 Visceral obesity and the heart. Int J Biochem Cell Biol 40:821-836
8. Taksali SE, Caprio S, Dziura J, Dufour S, Calí AM, Goodman TR, Papademetris X, Burgert TS, Pierpont BM, Savoye M, Shaw M, Seyal AA, Weiss R 2008 High visceral and low abdominal subcutaneous fat stores in the obese adolescent: a determinant of an adverse metabolic phenotype. Diabetes 57:367-371
9. Kelley DE, Thaete FL, Troost F, Huwe T, Goodpaster BH 2000 Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance. Am J Physiol Endocrinol Metab 278:E941-E948 (Pubitemid 30366413)
10. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S. Acromegaly Consensus Group 2010 A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141-3148
11. DeFronzo RA, Tobin JD, Andres R 1979 Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223 (Pubitemid 9249478)
12. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H; Type 1 Diabetes Trial Net Research Group; European C-Peptide Trial Study Group 2008 Mixed-meal tolerance test versus glucagon stimulation test for the assessment of β-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 31:1966-1971
13. Utzschneider KM, Prigeon RL, Faulenbach MV, Tong J, Carr DB, Boyko EJ, Leonetti DL, McNeely MJ, Fujimoto WY, Kahn SE 2009 Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 32:335-341
14. Amato MC, Giordano C, Pitrone M, Galluzzo A 2011 A Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids Health Dis 10:183
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 2001 Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497
16. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, Hellman R, Jellinger PS, Jovanovic LG, Levy P, Mechanick JI, Zangeneh F; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force 2007 American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 1(Suppl 1)3:1-68
17. Bozorgmanesh M, Hadaegh F, Azizi F 2011 Predictive performance of the visceral adiposity index for a visceral adiposity-related risk: type 2 diabetes. Lipids Health Dis 10:88
18. Petta S, Amato M, Cabibi D, Cammà C, Di Marco V, Giordano C, Galluzzo A, Craxì A 2010 Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Hepatology 52:1543-1552
19. Petta S, Amato MC, Di Marco V, Cammà C, Pizzolanti G, Barcellona MR, Cabibi D, Galluzzo A, Sinagra D, Giordano C, Craxì A 2012 Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 35:238-247
20. Amato MC, Verghi M, Galluzzo A, Giordano C 2011 The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk. Hum Reprod 26:1486-1494
21. Fieffe S, Morange I, Petrossians P, Chanson P, Rohmer V, Cortet C, Borson-Chazot F, Brue T, Delemer B; French Acromegaly Registry 2011 Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol 164:877-884
22. Kamenicky P, Viengchareun S, Blanchard A, Meduri G, Zizzari P, Imbert-Teboul M, Doucet A, Chanson P, Lombès M 2008 Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly. Endocrinology 149:3294-3305 (Pubitemid 351919590)
23. Horita S, Seki G, Yamada H, Suzuki M, Koike K, Fujita T 2011 Insulin resistance, obesity, hypertension, and renal sodium transport. Int J Hypertens 2011:391762
24. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW 2004 C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 53:250-264 (Pubitemid 38044724)
25. Parkinson C, Drake WM, Roberts ME, Meeran K, Besser GM, Trainer PJ 2002 A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J Clin Endocrinol Metab 87:1797-1804 (Pubitemid 34615271)
26. Giordano C, Ciresi A, Amato MC, Pivonello R, Auriemma RS, Grasso LF, Galluzzo A, Colao A 25 November 2011 Clinical and metabolic effects of first-line treatment with somatostatin analogs or surgery in acromegaly: a retrospective and comparative study. Pituitary 10.1007/s11102-011-0365-5
27. Higham CE, Rowles S, Russell-Jones D, Umpleby AM, Trainer PJ 2009 Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. J Clin Endocrinol Metab 94:2459-2463
28. Ertorer ME, Bakiner O, Anaforoglu I, Bozkirli E, Tutuncu NB, Demirag NG 2007 Lanreotide autogel and insulin sensitivity markers: report of 5 acromegalic patients and literature review. Neuro Endocrinol Lett 28:727-733
29. Lindberg-Larsen R, Møller N, Schmitz O, Nielsen S, Andersen M, Orskov H, Jørgensen JO 2007 The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab 92:1724-1728 (Pubitemid 46997178)
30. Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D'Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V, Tamburrano G 2003 Glucose homeostasis in acromegaly: effects of longacting somatostatin analogues treatment. Clin Endocrinol (Oxf) 59:492-499 (Pubitemid 37188181)
31. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I 2004 Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24:29-33 (Pubitemid 38082408)
32. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, Matsuzawa Y 2001 Circulating concentrations of the adipocyte protein adiponectin and decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50:1126-1133 (Pubitemid 32374544)
33. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA 2001 Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930-1935 (Pubitemid 32472900)
34. Damjanović SS, Petakov MS, Raicević S, Micić D, Marinković J, Dieguez C, Casanueva FF, Popović VJ 2000 Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery. J Clin Endocrinol Metab 85:147-154
35. Tan KC, Tso AW, Lam KS 2001 Effect of Sandostatin LAR on serum leptin levels in patients with acromegaly. Clin Endocrinol (Oxf) 54:31-35 (Pubitemid 32158702)
36. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF 1996 Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292-295 (Pubitemid 26033933)
37. Lam KS, Xu A, Tan KC, Wong LC, Tiu SC, Tam S 2004 Serum adiponectin is reduced in acromegaly and normalized after correction of growth hormone excess. J Clin Endocrinol Metab 89:5448-5453 (Pubitemid 39518424)
38. Ronchi CL, Corbetta S, Cappiello V, Morpurgo PS, Giavoli C, Beck-Peccoz P, Arosio M, Spada A 2004 Circulating adiponectin levels and cardiovascular risk factors in acromegalic patients. Eur J Endocrinol 150:663-669 (Pubitemid 38786536)
39. Lorenzo C, Haffner SM, Stancáková A, Laakso M 2010 Relation of direct and surrogate measures of insulin resistance to cardiovascular risk factors in nondiabetic finnish offspring of type 2 diabetic individuals J Clin Endocrinol Metab 95:5082-5090
40. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB 1995 The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95:2111-2119
41. Steensberg A, Fischer CP, Sacchetti M, Keller C, Osada T, Schjerling P, van Hall G, Febbraio MA, Pedersen BK 2003 Acute interleukin-6 administration does not impair muscle glucose uptake or wholebody glucose disposal in healthy humans. J Physiol 548:631-638 (Pubitemid 36527483)
42. Tarantino G, Lobello R, Scopacasa F, Contaldo F, Pasanisi F, Cirillo M, De Caterina M, Conca P, Terracciano D, Gennarelli N, Ariello M, Mazzarella C, Grimaldi E, Macchia V 2007 The contribution of omental adipose tissue to adipokine concentrations in patients with the metabolic syndrome. Clin Invest Med 30:E192-E199 (Pubitemid 350075000)
43. Bolanowski M, Daroszewski J, Zatonska K, Arkowska A 2006 Circulating cytokines in relation to bone mineral density changes in patients with acromegaly. Neuro Endocrinol Lett 27:183-188 (Pubitemid 43970791)
44. Després JP 2006 Is visceral obesity the cause of the metabolic syndrome? Ann Med 38:52-63